HealthDay News – Participants who were taught intensive therapy for type 1 diabetes during the Diabetes Control and Complications Trial (DCCT) experienced clinically beneficial effects on cardiovascular outcomes at 30 years of follow-up, according to research published in Diabetes Care.
The DCCT/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group assessed whether intensive therapy compared with conventional therapy during the DCCT (mean of 6.5 years) had an effect on the incidence of cardiovascular disease (CVD) over 30 years of follow-up.
Researchers found that at 30 years of follow-up in the DCCT and EDIC, 149 CVD events had occurred in 82 former participants from the intensive treatment group vs 217 CVD events in 102 of those from the conventional treatment group. For those in the intensive therapy group, the incidence of any CVD was reduced by 30% (95% confidence interval [CI]: 7%-48%; P=.016), and the incidence of major cardiovascular events (nonfatal myocardial infarction, stroke, or cardiovascular death) was reduced by 32% (95% CI: −3% to 56%; P=.07).
“Intensive diabetes therapy during the DCCT (6.5 years) has long-term beneficial effects on the incidence of [CVD] in type 1 diabetes that persist for up to 30 years,” the authors wrote.
Disclosures: Pharmaceutical and biomedical companies provided free or discounted supplies or equipment to participants in the study.
Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year follow-up. Diabetes Care. 2016. doi:10.2337/dc15-1990.